BioTrends Research Group, Inc. recently announced the release of their latest annual report regarding the management and treatment of multiple sclerosis (MS) in the US, which is compiled using data obtained directly from MS patients who are currently receiving treatment in the form of disease modifying agents (DMAs). The comprehensive report, titled ChartTrends: Multiple Sclerosis, [...]

Naltrexone is a drug that was initially developed in order to assist drug addicts to kick their drug habit, but was later found to be of significant benefit to sufferers of Multiple Sclerosis (MS) when prescribed in low doses. This has resulted in Low Dose Naltrexone (LDN) becoming an increasingly popular choice for the treatment [...]

New insights into the methods in which the immune system attacks the central nervous system in patients affected by Multiple Sclerosis (MS) have been discovered by researchers in Germany, who used imaging tools which enable the investigation of processes within living organisms. MS is an incurable autoimmune disease which causes the immune system to attack [...]

Sanofi-aventis (NYSE:SNY) recently announced clinical success with teriflunomide, the investigational drug it is developing for the treatment of relapsing multiple sclerosis (RMS). This announcement followed a 2-year clinical trial, in which teriflunomide was found to significantly improve the annualized relapse rate (ARR) of RMS in a group patients receiving the orally administered teriflunomide, when compared [...]

An expert panel from FDA has issued a recommendation for the agency to approve a new multiple sclerosis (MS) drug called Gilenia (known generically as fingolimod). Once it gets the final approval, it will be the first oral drug to treat multiple sclerosis. According to the National Multiple Sclerosis Society, MS affects more than 2.5 [...]